international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
revenue has continuously grown mainly due to its greater expansion of laboratory scopes of testing and analyzing for agricultural, food, and pharmaceutical associated with continual growing number of
by more efficient management of pharmaceutical supplies. Administrative Expenses During 9M17, administrative expenses increased by 14% yoy due mainly to the increase of headcounts and salary rate in
อร์ตี้ จำกัด (มหาชน) กรุณาระบุเงื่อนไขในการค้นหา ค้นหาบริษัท JP: JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED JSP: บริษัท เจ. เอส. พี. พร็อพเพอร์ตี้ จำกัด (มหาชน) ล้างเงื่อนไข
baht or 6. 56 percent from the previous year, mainly due to a decrease of drug and medical supply cost since the volume of general patients and social security patients decreased. Besides, the Company
quite a longer process of licenses than expected, e.g., import license and food serial number from the Food and Drug Administration (FDA). In addition, the Company is in the process of adjusting its
outsourced production with fully completed services, from formulation development, research, marketing and label design and packaging services, including cosmetic product filings with the Food and Drug